STADA Arzneimittel AG (ETR:SAZ) has been assigned a €65.53 ($78.01) price target by equities researchers at Nord/LB in a note issued to investors on Thursday. The brokerage currently has a “sell” rating on the stock.

Several other analysts have also recently weighed in on SAZ. Commerzbank Ag set a €66.00 ($78.57) price objective on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Saturday, May 20th. Warburg Research set a €66.00 ($78.57) price objective on shares of STADA Arzneimittel AG and gave the stock a “sell” rating in a research note on Saturday, May 20th. Independent Research GmbH set a €66.00 ($78.57) price target on shares of STADA Arzneimittel AG and gave the company a “neutral” rating in a research note on Saturday, May 20th. S&P Global set a €66.00 ($78.57) price target on shares of STADA Arzneimittel AG and gave the company a “neutral” rating in a research note on Saturday, May 20th. Finally, Kepler Capital Markets set a €62.50 ($74.40) price target on shares of STADA Arzneimittel AG and gave the company a “sell” rating in a research note on Thursday, June 22nd. Four equities research analysts have rated the stock with a sell rating and two have issued a hold rating to the company. The company has an average rating of “Sell” and an average price target of €67.71 ($80.61).

STADA Arzneimittel AG (ETR:SAZ) opened at 79.389 on Thursday. The firm has a market capitalization of €4.94 billion and a P/E ratio of 52.471. STADA Arzneimittel AG has a 52 week low of €41.40 and a 52 week high of €84.20. The firm has a 50-day moving average price of €69.09 and a 200-day moving average price of €63.47.

WARNING: This article was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/stada-arzneimittel-ag-saz-pt-set-at-65-53-by-nordlb/1537296.html.

About STADA Arzneimittel AG

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel AG (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with Analyst Ratings Network's FREE daily email newsletter.